Palisade Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Palisade Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,700	Closed	-$206K	–	452
2017 Q1	$206K	Sell	1,700 -1,300	-43%	-$168K	0.01%	416
2016 Q4	$367K	Buy	+3,000	New	+$367K	0.01%	424
2015 Q2	–	Sell	-2,201	Closed	-$381K	–	546
2015 Q1	$381K	Hold	2,201	–	–	0.01%	466
2014 Q4	$407K	Sell	2,201 -650	-23%	-$120K	0.01%	439
2014 Q3	$473K	Sell	2,851 -1,261	-31%	-$207K	0.01%	431
2014 Q2	$642K	Sell	4,112 -768	-16%	-$121K	0.02%	401
2014 Q1	$742K	Sell	4,880 -2,449	-33%	-$389K	0.02%	381
2013 Q4	$974K	Sell	7,329 -2,534	-26%	-$304K	0.03%	339
2013 Q3	$1.15M	Sell	9,863 -9,697	-50%	-$1.06M	0.03%	341
2013 Q2	$1.8M	Buy	+19,560	New	+$1.88M	0.05%	322

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Palisade Capital Management's ALXN Position: Q2 2017 in Review

Palisade Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 1,700 shares — an estimated $206K sold.

Palisade Capital Management first reported a position in ALXN in Q2 2013 and held it in 10 quarters. The position peaked at $1.8M in Q2 2013. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

Palisade Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Palisade Capital Management sold 1,700 Alexion Pharmaceuticals shares in Q2 2017, an estimated $206K.
Palisade Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Palisade Capital Management's Alexion Pharmaceuticals position peaked at $1.8M in Q2 2013.
559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Palisade Capital Management's 13F filing for Q2 2017, filed 1 Aug 2017.